@article{fd5b626183e44eebb1319d03224558ff,
title = "N95 respirator reuse, decontamination methods, and microbial burden: A randomized controlled trial",
abstract = "Purpose: To evaluate the effectiveness and ease of N95 respirator decontamination methods in a clinic setting and to identify the extent of microbial colonization on respirators associated with reuse. Methods: In a prospective fashion, N95 respirators (n = 15) were randomized to a decontamination process (time, dry heat, or ultraviolet C light [UVC]) in outpatient clinics. Each respirator was re-used up to 5 separate clinic sessions. Swabs on each respirator for SARS-CoV-2, bacteria, and fungi were obtained before clinic, after clinic and post-treatment. Mask integrity was checked after each treatment (n = 68). Statistical analyses were performed to determine factors for positive samples. Results: All three decontamination processes reduced bacteria counts similarly. On multivariate mixed model analysis, there were an additional 8.1 colonies of bacteria (95% CI 5.7 to 10.5; p < 0.01) on the inside compared to the outside surface of the respirators. Treatment resulted in a decrease of bacterial load by 8.6 colonies (95% CI -11.6 to −5.5; p < 0.01). Although no decontamination treatment affected the respirator filtration efficiency, heat treatments were associated with the breakdown of thermoplastic elastomer straps. Contamination with fungal and SARS-CoV-2 viral particles were minimal to non-existent. Conclusions: Time, heat and UVC all reduced bacterial load on reused N95 respirators. Fungal contamination was minimal. Heat could permanently damage some elastic straps making the respirators nonfunctional. Given its effectiveness against microbes, lack of damage to re-treated respirators and logistical ease, UVC represents an optimal decontamination method for individual N95 respirators when reuse is necessary.",
keywords = "Decontamination, N95 respirators, Reuse respirators, SARS-CoV-2",
author = "Jiang, {Zi Yang} and Zhen Huang and Isaac Schmale and Brown, {Eric L.} and Lorenz, {Michael C.} and Patlovich, {Scott J.} and Karan Goswami and Wilson, {Hannah B.} and Jumah Ahmad and Ronda Alexander and William Bryan and Luke Burke and Citardi, {Martin J.} and Jose Elias and Tang Ho and Jack Jacob and Garren Low and Pedro Miram{\'o}n and Patki, {Aniruddha U.} and Yao, {William C.} and Luong, {Amber U.}",
note = "Funding Information: This study was supported in part by NIH award R01AI143304 to M.C.L. We would like to thank MicroGenDx (Lubbock, TX) for providing swab collection and transport material and processing these swabs for SARs-CoV-2. We thank Drs. Ron Karni, Soham Roy and Arturo Eguia for their participation in this study. Finally, we thank Dr. W. Katherine Kao for her recommendations on the study protocol. Funding Information: This study was supported in part by NIH award R01AI143304 to M.C.L. We would like to thank MicroGenDx (Lubbock, TX) for providing swab collection and transport material and processing these swabs for SARs-CoV-2. We thank Drs. Ron Karni, Soham Roy and Arturo Eguia for their participation in this study. Finally, we thank Dr. W. Katherine Kao for her recommendations on the study protocol. MJC serves as a consultant for Acclarent (Irvine, CA), BioMed ENT (San Antonio, TX), Inquis Medical (Atherton, CA), Iodphor (Philadelphia, TX), MicroGenDx (Lubbock, TX), and Stryker (Kalamazoo, MI). AL serves as a consultant for Inquis Medical (Atherton, CA), Medtronic (Jacksonville, FL), and Stryker (Kalamazoo, MI). She is on the advisory board for ENTvantage (Austin, TX) and has served on advisory boards for Genetech (San Francisco, CA), AstraZeneca (Wilmington, DE) and Sanofi (Paris, France). WCY is a consultant for Stryker (Kalamazoo, MI) and speaker for Optinose (Yardley, PA). The Department of Otorhinolaryngology - Head & Neck Surgery, McGovern Medical School, The University of Texas Health Science Center at Houston, has received funding from Genetech/Roche (San Francisco, CA), AstraZeneca (Cambridge, England) and Optinose (Yardley, PA). Funding Information: The Department of Otorhinolaryngology - Head & Neck Surgery, McGovern Medical School, The University of Texas Health Science Center at Houston, has received funding from Genetech/Roche (San Francisco, CA), AstraZeneca (Cambridge, England) and Optinose (Yardley, PA). Publisher Copyright: {\textcopyright} 2021 Elsevier Inc.",
year = "2021",
month = sep,
day = "1",
doi = "10.1016/j.amjoto.2021.103017",
language = "English (US)",
volume = "42",
journal = "American Journal of Otolaryngology - Head and Neck Medicine and Surgery",
issn = "0196-0709",
publisher = "W.B. Saunders Ltd",
number = "5",
}